CD19

Viela Bio Announces Publication in The Lancet of Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder

Retrieved on: 
Friday, September 6, 2019
Research, Pharmaceutical, Publishing, Science, Cardiology, Biotechnology, Communications, FDA, Health, Monoclonal antibodies, Inebilizumab, Autoimmune diseases, Organ systems, Medical specialties, Immunology, Neuromyelitis optica, The Lancet, CD19, Multiple sclerosis, Neuromyelitis Optica Spectrum Disorders (NMOSD), Inebilizumab, N-MOmentum, Viela Bio

Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).

Key Points: 
  • Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).
  • This study provided key information on the safety and efficacy profile of inebilizumab monotherapy in NMOSD.
  • Inebilizumab is the first and only biologic to use CD19 as a target for B cell depletion in this devastating disease.
  • Continued Dr. Drappa: The results from this pivotal study are very encouraging, demonstrating the potential impact on patient care if inebilizumab is approved by the U.S. Food and Drug Administration.

Elicio Therapeutics Co-founder, Darrell Irvine, Co-authors Research Published in Science Demonstrating Novel AMP-CAR-T Approach to Enhance CAR-T Function in Solid Tumor Cancers

Retrieved on: 
Thursday, July 11, 2019
Research, Clinical trials, Biotechnology, Pharmaceutical, Health, Oncology, Science, Medicine, Clinical medicine, Health, Cancer treatments, Virotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Immunotherapy, CD19, Cancer

[1]

Key Points: 
  • [1]
    Through precise targeting and delivery directly to the lymphatic system, Elicio is engineering potent Amphiphile immunotherapies including cell therapy activators, immunomodulators, and vaccines for an array of aggressive cancers.
  • The company is currently utilizing the study findings in its AMP-CAR-T platform to develop therapeutic interventions that activate and amplify CAR-T therapy to combat an array of cancers including solid tumors.
  • Elicio is developing the AMP-CAR-T platform for combination with CAR-T cell therapies in a variety of settings including those targeting CD19, BCMA, and several solid tumor indications.
  • This strategy is highly flexible for universal application with any CAR-T therapy without the need for re-engineering of the CAR-T cell design.

Gracell Data on Multi-center Investigation of FasT CAR-19 Therapy Shows Positive First Impact in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Retrieved on: 
Thursday, June 20, 2019
Medicine, Clinical medicine, Medical specialties, RTT, Cancer treatments, Gene therapy, Pediatric cancers, Antibody-drug conjugates, Chimeric antigen receptor T cell, CD19, Lymphoma, Acute lymphoblastic leukemia

The customized treatment which genetically modifies patient's T-cells to express CD19-specific chimeric antigen receptor (CAR), showed a clinically meaningful and positive result in the treatment ofB-cell acute lymphoblastic leukemia (B-ALL).

Key Points: 
  • The customized treatment which genetically modifies patient's T-cells to express CD19-specific chimeric antigen receptor (CAR), showed a clinically meaningful and positive result in the treatment ofB-cell acute lymphoblastic leukemia (B-ALL).
  • However, for the many patients who develop relapsed or refractory (r/r) B-ALL, significant complications in treatment remain.
  • FasT CAR-19, or GC007F,is an investigational CD19-targeted CAR-T cell therapy for adolescent and adult patients with relapsed or refractory B-ALL, as well as aggressive non-Hodgkin lymphoma.
  • Gracell Biotechnologies Co., Ltd. ("Gracell") is a clinical-stage biopharma company, committed to developing highly reliable and affordable cell gene therapies for cancer.

Triumvira Immunologics Announces Clearance of IND and CTA by U.S. FDA and Health Canada for Its First TAC T-cell Therapeutic Product Candidate, TAC01-CD19

Retrieved on: 
Tuesday, June 18, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, FDA, Science, Medical specialties, Medicine, Branches of biology, Immune system, CD19, Chimeric antigen receptor T cell, B cell, Lymphocyte, T cell, Adoptive cell transfer, Kite Pharma

TAC01-CD19 will be tested at five leading lymphoma clinical study centers in the U.S. and Canada.

Key Points: 
  • TAC01-CD19 will be tested at five leading lymphoma clinical study centers in the U.S. and Canada.
  • Triumvira is developing a proprietary T Cell Antigen Coupler (TAC) technology platform which is biologically distinct from CAR-T.
  • The first of our pipeline product candidates, TAC01-CD19 is a novel T cell therapy product targeting CD19 for use in B-cell malignancies.
  • The product comprises patient-derived T cells that have been genetically engineered to express the CD19 T cell Antigen Coupler (TAC).

Triumvira Submits Investigational New Drug (IND) Application to the FDA and Clinical Trial Application (CTA) to Health Canada to Evaluate TAC01-CD19, a T Cell Antigen Coupler Therapy, in Ph 1/2 TACTIC-19 Trial

Retrieved on: 
Wednesday, May 1, 2019
Health, Biotechnology, Oncology, Pharmaceutical, FDA, Medical specialties, Medicine, Branches of biology, Immune system, Chimeric antigen receptor T cell, CD19, B cell, Lymphoma, T cell, Neprilysin, Lymphocyte, Kite Pharma

We look forward to opening our first of five prominent clinical trial sites in the early summer of 2019.

Key Points: 
  • We look forward to opening our first of five prominent clinical trial sites in the early summer of 2019.
  • Triumvira is developing a proprietary T Cell Antigen Coupler (TAC) technology platform which is biologically distinct from CAR-T and has the potential to be a next generation solution to these challenges.
  • The product comprises autologous T cells that have been genetically engineered via lentiviral transduction to express the CD19 T cell Antigen Coupler (TAC).
  • CD19 is a B cell marker and is expressed on the surface of B cell malignancies such as Diffuse Large B Cell Lymphoma (DLBCL).

Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR

Retrieved on: 
Tuesday, April 2, 2019
Medical specialties, Medicine, Clinical medicine, Monoclonal antibodies, Immune system, Immunology, CD19, Bi-specific T-cell engager, Cancer, Chimeric antigen receptor T cell, CD16

Results were presented as a poster at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta.

Key Points: 
  • Results were presented as a poster at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta.
  • Also presented was Inovio's CD19 dBiTE which can kill B cell cancers by targeting B cell specific marker CD19.
  • BiTEs are a class of artificial bi-specific monoclonal antibodies that has the potential to transform the immunotherapy landscape for cancer.
  • This double-binding activity drives T cell activation directly at the tumor resulting in a killing function and tumor destruction.

Reducing B Cells with Modified CAR T Cells is an Effective Treatment of Experimental Lupus

Retrieved on: 
Wednesday, March 6, 2019
Medical specialties, Medicine, Branches of biology, Immune system, Systemic lupus erythematosus, Chimeric antigen receptor T cell, CD19, B cell, Immunoglobulin E, Tumor antigens recognized by T lymphocytes, T helper cell

Given the central role and wide range of effects of B cells on lupus, it is not surprising that this cell type has been the subject of intense research in lupus for decades.

Key Points: 
  • Given the central role and wide range of effects of B cells on lupus, it is not surprising that this cell type has been the subject of intense research in lupus for decades.
  • The modified T cells recognize the CD19 molecule found on almost all B cells.
  • When mice with lupus were treated with these modified T cells called chimeric antigen receptor (CAR) T cells, disease symptoms and progression were significantly lessened.
  • The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world.

Global $33.71 Bn Cell Surface Markers Market to 2026 - Growing Health Awareness and Development of Healthcare Infrastructure to Drive the Market

Retrieved on: 
Tuesday, February 5, 2019
Medical specialties, Branches of biology, Medicine, Immunology, Immune system, T cells, Anatomical pathology, Antigens, Cluster of differentiation, CD19, CD34, Lymphocyte

Cell surface markers are proteins which are expressed on the surface of the cells which is useful in identifying the cell type.

Key Points: 
  • Cell surface markers are proteins which are expressed on the surface of the cells which is useful in identifying the cell type.
  • Cell surface markers are present for B lymphocytes, T lymphocytes, and cluster of differentiation (CD34+, CD4, CD19 etc.).
  • Increasing expenditure in the development of cell surface markers for drug discovery & development and the burgeoning requirement to reduce the cost associated with disease diagnosis drive the cell surface markers market.
  • The limitations associated with cell surface markers market are complex products and expensive instrument and reagents used in cell marker analysis.

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Journey From Target to T Cell Product: A Platform to Identify Opportunities and Overcome Challenges, 2018 by DelveInsight

Retrieved on: 
Thursday, January 17, 2019
Medicine, Cancer treatments, Immune system, Virotherapy, Chimeric antigen receptor, Gene therapy, CD19, Immunotherapy, T cell, Kite Pharma, Juno Therapeutics

Chimeric Antigen Receptor (CAR-T) - Market Scenario Collaborations, Opportunities, Pipeline development, Pricing and Reimbursement Policies, Market Potential, Unmet Needs etc.

Key Points: 
  • Chimeric Antigen Receptor (CAR-T) - Market Scenario Collaborations, Opportunities, Pipeline development, Pricing and Reimbursement Policies, Market Potential, Unmet Needs etc.
  • Approximately, more than 70 collaborations took place in this period, which included company-company as well as company-institution collaborations.
  • Additionally, CD19 antigen has had the maximum share in terms of target antigen, in comparison to other targets in developing CAR-T therapies.
  • DelveInsight's Report, "Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges, 2018", emphasizes on the currently active CAR-T cell products in research and development.

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Journey From Target to T Cell Product: A Platform to Identify Opportunities and Overcome Challenges, 2018 by DelveInsight

Retrieved on: 
Thursday, January 17, 2019
Medicine, Cancer treatments, Immune system, Virotherapy, Chimeric antigen receptor, Gene therapy, CD19, Immunotherapy, T cell, Kite Pharma, Juno Therapeutics

Chimeric Antigen Receptor (CAR-T) - Market Scenario Collaborations, Opportunities, Pipeline development, Pricing and Reimbursement Policies, Market Potential, Unmet Needs etc.

Key Points: 
  • Chimeric Antigen Receptor (CAR-T) - Market Scenario Collaborations, Opportunities, Pipeline development, Pricing and Reimbursement Policies, Market Potential, Unmet Needs etc.
  • Approximately, more than 70 collaborations took place in this period, which included company-company as well as company-institution collaborations.
  • Additionally, CD19 antigen has had the maximum share in terms of target antigen, in comparison to other targets in developing CAR-T therapies.
  • DelveInsight's Report, "Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges, 2018", emphasizes on the currently active CAR-T cell products in research and development.